About Us
The Health Thread
Ethical Health Journalism
Live
🌍Building Trust: Key to Stopping Rapid Ebola Spread in DR Congo🌍Ebola Spreads in DR Congo: Local Leaders Combat Misinformation for Early Detection🌍Ebola Vaccine Trial Recommended for Bundibugyo Virus in DR Congo🌍Jalapeño-Linked Salmonella Alert: Check Your Meat and Poultry Products Now🌍Ebola Emergency: Urgent Community-Led Action Needed in DR Congo, Say Africa CDC and WHO🌍Building Trust: Key to Stopping Rapid Ebola Spread in DR Congo🌍Ebola Spreads in DR Congo: Local Leaders Combat Misinformation for Early Detection🌍Ebola Vaccine Trial Recommended for Bundibugyo Virus in DR Congo🌍Jalapeño-Linked Salmonella Alert: Check Your Meat and Poultry Products Now🌍Ebola Emergency: Urgent Community-Led Action Needed in DR Congo, Say Africa CDC and WHO
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data.

Researchers

Chao Zhu, Sandra Vukusic, Tomas Kalincik, Guillaume Mathey, Allan G Kermode, Elisabeth Maillart, Jeannette Lechner-Scott, Emanuelle Le Page, Izanne Roos, Jonathan Ciron, Eva Kubala Havrdova, Dana Horakova, Jérôme De Sèze, Olga Skibina, Aurelie Ruet, Mehmet Fatih Yetkin, Pierre Labauge, Mario Habek, Arnaud Kwiatkowski, Seyed Mohammad Baghbanian, Helene Zephir, Jose E Meca-Lallana, Gabriel Valero López, Caroline Papeix, Oliver Gerlach, Gilles Defer, Marzena Fabis-Pedrini, William M Carroll, Christine Lebrun-Frenay, Suzanne Hodgkinson, Thibault Moreau, Guy Laureys, David-Axel Laplaud, Alexandre Prat, Eric Berger, Emmanuelle Lapointe, Pierre Clavelou, Radek Ampapa, Eric Thouvenot, Ivana Stetkarova, Olivier Heinzlef, Pavel Stourac, Jean Pelletier, Matteo Foschi, Abdullatif Al Khedr, Emanuele D'Amico, Olivier Casez, Raed Alroughani, Bertrand Bourre, Gregor Brecl Jakob, Alain Creange, Serkan Ozakbas, Thomas David, Nevin John, Laurent Magy, Jean-Philippe Camdessanché, Solène Moulin, Ines Doghri, Mariana Sarov Riviere, Karolina Hankiewicz, Corinne Pottier, Eric Manchon, Jennifer Aboab, Maia Tchikviladze, Chantal Nifle, Daniel Merlo, Mastura Monif, Zhen Zhou, Yi Chao Foong, Vilija Jokubaitis, Anneke van der Walt, Helmut Butzkueven

Abstract

Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice. We conducted an observational cohort study emulating a target trial using data from the MSBase and Observatoire Français de la Sclérose en Plaques registries (January 2021 to December 2024). Adults with RRMS initiating ofatumumab or ocrelizumab were included. Patients were matched 1:1 using propensity scores. Primary outcomes were annualised relapse rate (ARR) and time to first relapse. Secondary outcomes included time to confirmed disability progression (CDP), progression independent of relapse activity (PIRA), confirmed disability improvement (CDI), MRI activity and treatment discontinuation. Negative binomial and Cox regression models were applied. A total of 5288 patients were matched with a median follow-up of 1.2 years for ofatumumab and 1.4 years for ocrelizumab. ARR was 0.07 (95% CI 0.05 to 0.08) with ofatumumab and 0.04 (0.03 to 0.05) with ocrelizumab, corresponding to an ARR ratio of 1.75 (1.43 to 2.13). Ofatumumab was associated with a lower risk of CDP (HR 0.66; 0.49 to 0.87) and PIRA (0.53; 0.39 to 0.73), but a lower probability of CDI (0.76; 0.60 to 0.96). No significant differences were observed in MRI activity or treatment discontinuation. Both therapies were highly effective in a large cohort of patients with RRMS, with very low relapse or CDP rates. Ofatumumab was associated with slightly greater disability control, while ocrelizumab more effectively suppressed relapses. These differences were modest, and their clinical relevance requires further evidence and should be interpreted with caution.
Source: PubMed (PMID: 42601218)View Original on PubMed